| Diana Fernandez Garcia, MD | |
|
316 Ave Gen Valero, Fajardo, PR 00738-4848 | |
| (787) 860-3400 | |
| (787) 863-2075 |
| Full Name | Diana Fernandez Garcia |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 44 Years |
| Location | 316 Ave Gen Valero, Fajardo, Puerto Rico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639162191 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085B0100X | Radiology - Body Imaging | 5767 (Puerto Rico) | Primary |
| Entity Name | Fajardo Imaging Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871646372 PECOS PAC ID: 4082888417 Enrollment ID: O20111122000377 |
News Archive
Hispanic middle school children, at high risk for being overweight or obese, reduced their Body Mass Index (BMI) when they adhered to a nutrition intervention that included a snack of peanuts, compared to those children who did not.
Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.
New research by biologists at the University of York could lead to improved methods of detection for early-onset Parkinson's Disease (PD).
A new approach to behavior change which has been shown to successfully change hygiene, nutrition and exercise-related behaviors is described in a paper published in Health Psychology Review.
Warner Chilcott plc today announced its results for the quarter ended September 30, 2009. Revenue in the quarter ended September 30, 2009 increased 9.0% to $252.8 million over the prior year quarter. The primary drivers of the increase in revenue in the quarter were the net sales of LOESTRIN 24 FE and ESTRACE Cream which were partially offset by net sales declines of other products, primarily TACLONEX.
› Verified 3 days ago
| Entity Name | Fajardo Imaging Mri Csp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295896587 PECOS PAC ID: 2466626791 Enrollment ID: O20111122000471 |
News Archive
Hispanic middle school children, at high risk for being overweight or obese, reduced their Body Mass Index (BMI) when they adhered to a nutrition intervention that included a snack of peanuts, compared to those children who did not.
Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.
New research by biologists at the University of York could lead to improved methods of detection for early-onset Parkinson's Disease (PD).
A new approach to behavior change which has been shown to successfully change hygiene, nutrition and exercise-related behaviors is described in a paper published in Health Psychology Review.
Warner Chilcott plc today announced its results for the quarter ended September 30, 2009. Revenue in the quarter ended September 30, 2009 increased 9.0% to $252.8 million over the prior year quarter. The primary drivers of the increase in revenue in the quarter were the net sales of LOESTRIN 24 FE and ESTRACE Cream which were partially offset by net sales declines of other products, primarily TACLONEX.
› Verified 3 days ago
| Entity Name | Metro Pavia Healthcare Centers Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760723696 PECOS PAC ID: 8022232271 Enrollment ID: O20160630000203 |
News Archive
Hispanic middle school children, at high risk for being overweight or obese, reduced their Body Mass Index (BMI) when they adhered to a nutrition intervention that included a snack of peanuts, compared to those children who did not.
Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.
New research by biologists at the University of York could lead to improved methods of detection for early-onset Parkinson's Disease (PD).
A new approach to behavior change which has been shown to successfully change hygiene, nutrition and exercise-related behaviors is described in a paper published in Health Psychology Review.
Warner Chilcott plc today announced its results for the quarter ended September 30, 2009. Revenue in the quarter ended September 30, 2009 increased 9.0% to $252.8 million over the prior year quarter. The primary drivers of the increase in revenue in the quarter were the net sales of LOESTRIN 24 FE and ESTRACE Cream which were partially offset by net sales declines of other products, primarily TACLONEX.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Diana Fernandez Garcia, MD Po Box 490, Puerto Real, PR 00740-0490 Ph: (787) 860-3400 | Diana Fernandez Garcia, MD 316 Ave Gen Valero, Fajardo, PR 00738-4848 Ph: (787) 860-3400 |
News Archive
Hispanic middle school children, at high risk for being overweight or obese, reduced their Body Mass Index (BMI) when they adhered to a nutrition intervention that included a snack of peanuts, compared to those children who did not.
Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.
New research by biologists at the University of York could lead to improved methods of detection for early-onset Parkinson's Disease (PD).
A new approach to behavior change which has been shown to successfully change hygiene, nutrition and exercise-related behaviors is described in a paper published in Health Psychology Review.
Warner Chilcott plc today announced its results for the quarter ended September 30, 2009. Revenue in the quarter ended September 30, 2009 increased 9.0% to $252.8 million over the prior year quarter. The primary drivers of the increase in revenue in the quarter were the net sales of LOESTRIN 24 FE and ESTRACE Cream which were partially offset by net sales declines of other products, primarily TACLONEX.
› Verified 3 days ago
Dr. Javier J Perez, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 301 General Valero, Fajardo, PR 00738 Phone: 787-863-5768 | |
Dr. Ricardo Rene Rivera Fernandez, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 316 Ave General Valero, Fajardo, PR 00738 Phone: 787-860-3400 |